Mnemonic

Insulin Preparations

A memory aid for the classes of insulin by duration of action.

Expansion

Rapid, short, intermediate and long acting, matched to basal and prandial needs

Mnemonic

Group by how fast and how long:

  • Rapid acting analogues - lispro, aspart, glulisine. Onset 10 to 20 minutes, last 3 to 5 hours. Given with meals
  • Short acting (soluble, human) - Actrapid. Onset 30 minutes, lasts 8 hours. The one used in variable rate intravenous infusions
  • Intermediate - isophane (NPH). Lasts 12 to 18 hours
  • Long acting analogues - glargine, detemir, degludec. Flat, peakless, 24 hours or more

“Rapid with the meal, long once a day”, which is the logic of the basal bolus regimen: a long acting background plus a rapid acting dose with each meal.

Only soluble human insulin is given intravenously, because the analogues offer no advantage when infused.

Regimens: basal bolus for type 1 and for flexibility; twice daily mixed for a fixed routine; once daily long acting added to oral agents in type 2.

Never omit basal insulin in type 1 diabetes, even when the patient is nil by mouth, because doing so precipitates ketoacidosis regardless of the glucose.

Expansion

Class Onset Peak Duration Examples
Rapid analogue 10 to 20 min 1 h 3 to 5 h Lispro, aspart, glulisine
Short (soluble) 30 min 2 to 3 h 6 to 8 h Actrapid
Intermediate 1 to 2 h 4 to 8 h 12 to 16 h Isophane (NPH)
Long analogue 1 to 2 h Flat 20 to 24 h+ Glargine, detemir, degludec

Regimens

  • Basal bolus: long acting once daily plus rapid acting with meals. Most flexible and closest to physiology
  • Twice daily mixed: fewer injections but requires fixed meal timing
  • Continuous subcutaneous infusion (pump): rapid-acting insulin only, with a programmable basal rate

Two overnight phenomena worth distinguishing:

  • Dawn phenomenon: an early morning rise in glucose from the normal surge of growth hormone and cortisol. Managed by increasing basal insulin
  • Somogyi effect: rebound hyperglycaemia after nocturnal hypoglycaemia. Managed by reducing it. Continuous glucose monitoring distinguishes them